65,437 trials
Hyperhidrosis
Primary: Comparison of Mean Average (Standard Deviation) Total Palmar Gravimetric Sweat Production (GMSP) Between Subject Groups (Adult Patients With Hyperhidrosis Versus Healthy…
Crohn's Disease
Primary: Percentage of Patients Achieving Clinical Remission (Based on CDAI) at Week 54 — 144; 36 Participants — p=<0.0001
Stress Disorders, Post-Traumatic · Brain Injuries, Traumatic
Primary: Depression - Patient Health Questionnaire - 9 (PHQ-9) — 4.4; 6.3 units on a scale
Myopia
Primary: Lens Handling on Lens Removal — 8.4; 8.9 units on a scale
Malignant Glioma
Primary: Maximum Tolerated Dose (MTD) — 200 mg
Primary Immunodeficiency Diseases (PID)
Primary: Rate Represented as Mean Number of Acute Serious Bacterial Infections (ASBI) Per Participant-year — 0.04 ASBI per participant-year
Malignant Mesothelioma (MPM)
Primary: Overall Response Rate — 2; 8; 1; 4 Participants
Depressive Disorder, Major
Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 4 — -20.1; -19.9 Units on a scale — p=0.88
Menorrhagia · Heavy Menstrual Bleeding · Heavy Uterine Bleeding
Primary: Number of Trial Participants With Reduction in Menstrual Bleeding (PBLAC Score of ≤75) — 102 Participants
Idiopathic Pulmonary Fibrosis
Primary: Incidence and Severity of Adverse Events — 1; 0; 3; 2 Participants
Limb-Girdle Muscular Dystrophies · Facioscapulohumeral Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 4; 14; 0; 0 Participants
Osteoarthritis
Primary: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Likert (LK) 3.1 Pain Subscale Change From Baseline to 12 Months — -5.6; -5.4 score on a scale
HIV/AIDS · Smoking Cessation · Tobacco Use Disorder
Primary: Duration of Daily App Use — 12; 1.05 minutes — p=0.51
Metastatic Breast Cancer
Primary: Progression Free Survival — 7.0; 4.9 months — p==0.002
Pulmonary Disease, Chronic Obstructive
Primary: Incidence Rate of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation After Cohort Entry — 0.28; 0.32 exacerbation per patient-year — p=0.064